Common use of Operations Clause in Contracts

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, and any related or similar rules, regulations, or guidelines, issued, administered, or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, or proceeding by or before any court or governmental agency, authority, or body or any arbitrator involving the Company or any of its Subsidiaries respecting the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 30 contracts

Sources: At the Market Issuance Sales Agreement (ENDRA Life Sciences Inc.), At the Market Issuance Sales Agreement (Auddia Inc.), At the Market Issuance Sales Agreement (bioAffinity Technologies, Inc.)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company or its Subsidiaries (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 29 contracts

Sources: At the Market Issuance Sales Agreement (Airgain Inc), At the Market Issuance Sales Agreement (Airgain Inc), At the Market Issuance Sales Agreement (Microvision, Inc.)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 27 contracts

Sources: Sales Agreement (NightHawk Biosciences, Inc.), Sales Agreement (HTG Molecular Diagnostics, Inc), At Market Issuance Sales Agreement (Synthetic Biologics, Inc.)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or and its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 12 contracts

Sources: Equity Distribution Agreement (Spire Global, Inc.), Equity Distribution Agreement (Spire Global, Inc.), Equity Distribution Agreement (Clever Leaves Holdings Inc.)

Operations. The operations of the Company and its the Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its the Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 12 contracts

Sources: At the Market Equity Offering Sales Agreement (LIGHTBRIDGE Corp), At Market Issuance Sales Agreement (Evoke Pharma Inc), At Market Issuance Sales Agreement (Conatus Pharmaceuticals Inc.)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 11 contracts

Sources: Sales Agreement (Liquid Media Group Ltd.), At Market Issuance Sales Agreement (Acasti Pharma Inc.), At Market Issuance Sales Agreement (Aeterna Zentaris Inc.)

Operations. The operations of the Company and its the Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its the Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agencyagency having jurisdiction over the Company, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 10 contracts

Sources: At Market Issuance Sales Agreement (Actinium Pharmaceuticals, Inc.), At Market Issuance Sales Agreement (Ashford Inc.), At Market Issuance Sales Agreement (Sorrento Therapeutics, Inc.)

Operations. The operations of the Company and its the Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its the Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 5 contracts

Sources: At Market Issuance Sales Agreement (American Superconductor Corp /De/), Underwriting Agreement (American Superconductor Corp /De/), At Market Issuance Sales Agreement (American Superconductor Corp /De/)

Operations. The operations of the Company and its the Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its the Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction authority over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body having authority over the Company or any arbitrator involving the Company or any of its Subsidiaries respecting Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 4 contracts

Sources: At Market Issuance Sales Agreement (Moleculin Biotech, Inc.), At Market Issuance Sales Agreement (Moleculin Biotech, Inc.), At Market Issuance Sales Agreement (Moleculin Biotech, Inc.)

Operations. The operations of the Company Company, the Operating Partnership, and its the Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its the Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 4 contracts

Sources: At Market Issuance Sales Agreement (Physicians Realty Trust), At Market Issuance Sales Agreement (Physicians Realty Trust), At Market Issuance Sales Agreement (Physicians Realty Trust)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 2 contracts

Sources: Sales Agreement (Relypsa Inc), Sales Agreement (Relypsa Inc)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Bank Secrecy Act of 1970, as amended, also known as the Currency and Foreign Transactions Reporting Act of 1970, as amendedAct, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company Governmental Authority (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, or body or any arbitrator Governmental Authority involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 2 contracts

Sources: Sales Agreement (Caledonia Mining Corp PLC), Sales Agreement (Caledonia Mining Corp PLC)

Operations. The operations of the Company and its Subsidiaries the Subsidiary are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries the Subsidiary are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting the Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 2 contracts

Sources: At Market Issuance Sales Agreement (Coronado Biosciences Inc), At Market Issuance Sales Agreement (Coronado Biosciences Inc)

Operations. The operations of the Company and its the Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its the Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 2 contracts

Sources: At Market Issuance Sales Agreement (NephroGenex, Inc.), At Market Issuance Sales Agreement (NephroGenex, Inc.)

Operations. The operations of the Company and its Subsidiaries the Subsidiary are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries the Subsidiary are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company or the Subsidiary (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting the Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: At Market Issuance Sales Agreement (Pluristem Therapeutics Inc)

Operations. The operations of the Company and its the Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its the Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its the Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: At Market Issuance Sales Agreement (Fortress Biotech, Inc.)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or and its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company Governmental Authority (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, or body or any arbitrator Governmental Authority involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: At Market Issuance Sales Agreement (Bionano Genomics, Inc)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator having jurisdiction involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: Sales Agreement (Relmada Therapeutics, Inc.)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the "Money Laundering Laws"), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: At Market Issuance Sales Agreement (Aeterna Zentaris Inc.)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company or its Subsidiaries (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: Sales Agreement (Sophiris Bio Inc.)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company or its subsidiaries (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: At Market Issuance Sales Agreement (Telik Inc)

Operations. The operations of the Company and its Subsidiaries the Subsidiary are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries the Subsidiary are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company or the Subsidiary (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting the Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: At the Market Issuance Sales Agreement (Oncogenex Pharmaceuticals, Inc.)

Operations. The operations of the Company and its the Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its the Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction authority over the Company (collectively, the “Money Laundering LawsLaws ”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body having authority over the Company or any arbitrator involving the Company or any of its Subsidiaries respecting Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: At Market Issuance Sales Agreement (Moleculin Biotech, Inc.)

Operations. The operations of the Company and its the Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its the Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse EffectChange; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: Open Market Sale Agreement (LIGHTBRIDGE Corp)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are is subject, the rules and regulations thereunder, thereunder DOCPROPERTY "DocID" \* MERGEFORMAT DM3\9994766.4 and any related or similar rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, authority or body or any arbitrator involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: At Market Issuance Sales Agreement (Geron Corp)

Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder, thereunder and any related or similar applicable rules, regulations, regulations or guidelines, issued, administered, administered or enforced by any governmental agency Governmental Authority having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, suit or proceeding by or before any court or governmental agency, authority, or body or any arbitrator Governmental Authority involving the Company or any of its Subsidiaries respecting with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

Appears in 1 contract

Sources: Sales Agreement (Array Biopharma Inc)